SparingVision
Thierry Léveillard, PhD on Cellular and Molecular Biology, is Inserm Director or Research at Vision Institute (Paris) and head of Genetics Department. After several years of research in USA, in at UCSD and the Salk Institute and UCSC, he joined Genetics, Cellular and Molecular Biology Institute (IGBMC), then the Inserm laboratory at Strasbourg Louis Pasteur University. Author of several scientific reference publications in the field of genetics, he is co-founder, among other, of Rod derived Cone Viability Factor, the RdCVF.
He has received numerous international awards, including the 1997 Neuronal Plasticity IPSEN Award, the 2005 Foundation Fighting Blindness (FFB) Trustee Award and the 2015 Prix de la fondation de l’oeil (Fondation de France). Thierry Léveillard is founder and, as scientific adviser for SparingVision, intervenes in all the phases of R and D regarding development of the viral vectors, in particular the realization of preclinical regulatory.
This person is not in the org chart
This person is not in any offices
SparingVision
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration.